• 1
    Slater AFGChloroquine: mechanism of drug action and resistance inPlasmodium falciparum. Pharmac Ther1993; 57: 203235
  • 2
    Titus EORecent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine.Ther Drug Monit1989; 11: 369379
  • 3
    White NJClinical pharmacokinetics of antimalarial drugs.Clin Pharmacokin1985; 10: 187215
  • 4
    Wolheim FA, Hanson A, Laurell C-BChloroquine treatment in rheumatoid arthritis.Scand J Rheumatol1978; 7: 171176
  • 5
    Rothfield NEfficacy of antimalarials in systemic lupus erythematosus.Am J Med1988; 85: 5356
  • 6
    Laaksonen A-L, Koskiahde V, Juva KDosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus.Scand J Rheumatol1974; 3: 103108
  • 7
    Blazar BR, Whitley CB, Kitabchi AE,et alIn vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance.Diabetes1984; 33: 11331137
  • 8
    Smith GD, Amos TAS, Mahler R, Peters TJEffect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin-dependent diabetes mellitus.Br Med J1987; 294: 465467
  • 9
    Lancaster DL, Adio RA, Tai KK,et al. Inhibition of metoprolol metabolism by chloroquine and other antimalarial drugs.J Pharm Pharmacol1990; 42: 267271
  • 10
    Emerole GO, Thabrew MIChanges in some rat hepatic microsomal components induced by prolonged administration of chloroquine.Biochem Pharmacol1983; 32: 30053009
  • 11
    Nwankwo JO, Garba MA, Chinje CE, Mgbojikwe LO, Emerole GOPossible chloroquine-induced modification of N-acetylation of isoniazid and sulphadimidine in the rat.Biochem Pharmacol1990; 40: 654659
  • 12
    Cotton DWK, Sutorius AHMInhibiting effect of some antimalarial substances on glucose-6-phosphate dehydrogenase.Nature1971; 233: 197
  • 13
    Roskoski RJrJaskunas SRChloroquine and primaquine inhibition of rat liver cell-free polynucleotide-dependent polypeptide synthesis.Biochem Pharmacol1972; 21: 391399
  • 14
    Lefler CF, Lilja HS, Holbrook DJ,Inhibition of aminoacylation and polypeptide synthesis by chloroquine and primaquine in rat liver in vitro.Biochem Pharmacol1973; 22: 715728
  • 15
    Masimirembwa CM, Gustafsson LL, Dahl M-L, Abdi YA, Hasler JALack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes.Br J Clin Pharmacol1996; 41: 344346
  • 16
    Back DJ, Riviere JHInhibition of hepatic drug metabolism by quinoline derivatives in vitro.Br J Pharmacol1986; 86: 801P.
  • 17
    Fuhr U, Rost KLSimple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and saliva.Pharmacogenetics1994; 4: 109116
  • 18
    Goldstein JA, Faletto MB, Romkes-Sparks M,et al. Evidence that CYP2C19 is the major (S )-mephenytoin 4′-hydroxylase in humans.Biochemistry1994; 33: 17431752
  • 19
    Eichelbaum M, Bertilsson L, Säwe J, Zekorn CPolymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.Clin Pharmacol Ther1982; 31: 184186
  • 20
    Kharasch ED, Thummel KE, Mhyre J, Lillibridge JHSingle-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1.Clin Pharmacol Ther1993; 53: 643650
  • 21
    May DG, Arns PA, Richards WO,et al. The disposition of dapsone in cirrhosis.Clin Pharmacol Ther1992; 51: 689700
  • 22
    May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RAThe contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.Clin Pharmacol Ther1990; 48: 619627
  • 23
    Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RAValidation of the ‘Pittsburgh Cocktail’ approach to assess selective regulation of drug metabolizing enzymes.Clin Pharmacol Ther1997;62: 365376
  • 24
    Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RAMephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.Clin Pharmacol Ther1984; 36: 773780
  • 25
    Yue QY, Hassleström J, Svensson JO, Säwe JPharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine.Br J Clin Pharmacol1991; 31: 635642
  • 26
    Chen ZR, Somogyi AA, Reynolds G, Bochner FDisposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers.Br J Clin Pharmacol1991; 31: 381390
  • 27
    Otton SV, Schadel M, Cheung SW, Kaplan HL, Busto UE, Sellers EMCYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.Clin Pharmacol Ther1993; 54: 463472
  • 28
    Eichelbaum M, Gross ASThe genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects. Pharmac Ther1990; 46: 377394